{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T23:44:05Z","timestamp":1790811845656,"version":"4.1.0"},"reference-count":40,"publisher":"American Medical Association (AMA)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Ophthalmol"],"published-print":{"date-parts":[[2019,4,1]]},"DOI":"10.1001\/jamaophthalmol.2018.6902","type":"journal-article","created":{"date-parts":[[2019,2,7]],"date-time":"2019-02-07T21:25:59Z","timestamp":1549574759000},"page":"399","source":"Crossref","is-referenced-by-count":103,"title":["Immune Response and Intraocular Inflammation in Patients With Leber Hereditary Optic Neuropathy Treated With Intravitreal Injection of Recombinant Adeno-Associated Virus 2 Carrying the <i>ND4<\/i> Gene"],"prefix":"10.1001","volume":"137","author":[{"given":"C\u00e9line","family":"Bouquet","sequence":"first","affiliation":[{"name":"GenSight Biologics, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Vignal Clermont","sequence":"additional","affiliation":[{"name":"Centre Hospitalier National d\u2019Ophtalmologie des Quinze-Vingts, Paris, France"},{"name":"Rothschild Ophthalmology Foundation Hospital, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Galy","sequence":"additional","affiliation":[{"name":"GenSight Biologics, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serge","family":"Fitoussi","sequence":"additional","affiliation":[{"name":"GenSight Biologics, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laure","family":"Blouin","sequence":"additional","affiliation":[{"name":"GenSight Biologics, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marion R.","family":"Munk","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Bern Photographic Reading Center, Bern, Switzerland"},{"name":"Inselspital, University Hospital Bern Ober\u00e4rztin, Bern, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonia","family":"Valero","sequence":"additional","affiliation":[{"name":"GenSight Biologics, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandrine","family":"Meunier","sequence":"additional","affiliation":[{"name":"GenSight Biologics, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barrett","family":"Katz","sequence":"additional","affiliation":[{"name":"GenSight Biologics, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Alain","family":"Sahel","sequence":"additional","affiliation":[{"name":"Centre Hospitalier National d\u2019Ophtalmologie des Quinze-Vingts, Paris, France"},{"name":"Rothschild Ophthalmology Foundation Hospital, Paris, France"},{"name":"Sorbonne Universit\u00e9s, UPMC Univ Paris 06, INSERM, CNRS, Institut de la Vision, Paris, France"},{"name":"Department of Ophthalmology, University of Pittsburgh School of Medicine, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nitza","family":"Thomasson","sequence":"additional","affiliation":[{"name":"GenSight Biologics, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"2","key":"eoi180115r1","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.preteyeres.2010.11.002","article-title":"Mitochondrial optic neuropathies\u2014disease mechanisms and therapeutic strategies.","volume":"30","author":"Yu-Wai-Man","year":"2011","journal-title":"Prog Retin Eye Res"},{"issue":"2","key":"eoi180115r2","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1086\/346066","article-title":"The epidemiology of Leber hereditary optic neuropathy in the North East of England.","volume":"72","author":"Yu-Wai-Man","year":"2003","journal-title":"Am J Hum Genet"},{"issue":"5","key":"eoi180115r3","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1055\/s-00000071","article-title":"Therapeutic approaches to inherited optic neuropathies.","volume":"35","author":"Yu-Wai-Man","year":"2015","journal-title":"Semin Neurol"},{"key":"eoi180115r4","first-page":"1165","article-title":"Leber hereditary optic neuropathy: current perspectives.","volume":"9","author":"Meyerson","year":"2015","journal-title":"Clin Ophthalmol"},{"issue":"1","key":"eoi180115r5","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1093\/brain\/93.1.121","article-title":"A new manifestation of Leber\u2019s disease and a new explanation for the agency responsible for its unusual pattern of inheritance.","volume":"93","author":"Wallace","year":"1970","journal-title":"Brain"},{"issue":"4884","key":"eoi180115r6","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1126\/science.3201231","article-title":"Mitochondrial DNA mutation associated with Leber\u2019s hereditary optic neuropathy.","volume":"242","author":"Wallace","year":"1988","journal-title":"Science"},{"issue":"3","key":"eoi180115r7","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/j.ajo.2005.03.017","article-title":"Hereditary optic neuropathies: from the mitochondria to the optic nerve.","volume":"140","author":"Newman","year":"2005","journal-title":"Am J Ophthalmol"},{"issue":"3","key":"eoi180115r8","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1002\/(ISSN)1531-8249","article-title":"Biochemical features of mtDNA 14484 (ND6\/M64V) point mutation associated with Leber\u2019s hereditary optic neuropathy.","volume":"45","author":"Carelli","year":"1999","journal-title":"Ann Neurol"},{"issue":"2","key":"eoi180115r9","first-page":"325","article-title":"Longitudinal study of a heteroplasmic 3460 Leber hereditary optic neuropathy family by multiplexed primer-extension analysis and nucleotide sequencing.","volume":"58","author":"Ghosh","year":"1996","journal-title":"Am J Hum Genet"},{"issue":"2","key":"eoi180115r10","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.spen.2017.06.001","article-title":"Dominant optic atrophy and leber\u2019s hereditary optic neuropathy: update on clinical features and current therapeutic approaches.","volume":"24","author":"Chun","year":"2017","journal-title":"Semin Pediatr Neurol"},{"issue":"Pt 9","key":"eoi180115r11","doi-asserted-by":"publisher","first-page":"2677","DOI":"10.1093\/brain\/awr170","article-title":"A randomized placebo-controlled trial of idebenone in Leber\u2019s hereditary optic neuropathy.","volume":"134","author":"Klopstock","year":"2011","journal-title":"Brain"},{"issue":"11","key":"eoi180115r12","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1038\/nri1224","article-title":"Ocular immune privilege: therapeutic opportunities from an experiment of nature.","volume":"3","author":"Streilein","year":"2003","journal-title":"Nat Rev Immunol"},{"issue":"11","key":"eoi180115r13","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1016\/j.it.2008.08.002","article-title":"Immune regulation and the eye.","volume":"29","author":"Stein-Streilein","year":"2008","journal-title":"Trends Immunol"},{"issue":"4","key":"eoi180115r14","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1001\/jamaophthalmol.2013.7971","article-title":"Trial end points and natural history in patients with G11778A Leber hereditary optic neuropathy: preparation for gene therapy clinical trial.","volume":"132","author":"Lam","year":"2014","journal-title":"JAMA Ophthalmol"},{"issue":"2","key":"eoi180115r15","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1038\/gt.2011.151","article-title":"Novel adeno-associated viral vectors for retinal gene therapy.","volume":"19","author":"Vandenberghe","year":"2012","journal-title":"Gene Ther"},{"issue":"16","key":"eoi180115r16","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.1016\/j.visres.2008.05.005","article-title":"Barriers for retinal gene therapy: separating fact from fiction.","volume":"48","author":"Kumar-Singh","year":"2008","journal-title":"Vision Res"},{"issue":"11","key":"eoi180115r17","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1038\/sj.gt.3302039","article-title":"Immune responses to adeno-associated virus and its recombinant vectors.","volume":"10","author":"Sun","year":"2003","journal-title":"Gene Ther"},{"key":"eoi180115r18","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1016\/j.ebiom.2016.07.002","article-title":"Long-term outcomes of gene therapy for the treatment of Leber\u2019s hereditary optic neuropathy.","volume":"10","author":"Yang","year":"2016","journal-title":"EBioMedicine"},{"issue":"3","key":"eoi180115r19","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1016\/j.ophtha.2015.10.025","article-title":"Gene therapy for Leber hereditary optic neuropathy: initial results.","volume":"123","author":"Feuer","year":"2016","journal-title":"Ophthalmology"},{"key":"eoi180115r20","doi-asserted-by":"publisher","first-page":"21587","DOI":"10.1038\/srep21587","article-title":"Efficacy and safety of rAAV2-ND4 treatment for Leber\u2019s hereditary optic neuropathy.","volume":"6","author":"Wan","year":"2016","journal-title":"Sci Rep"},{"issue":"11","key":"eoi180115r21","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1016\/j.ophtha.2017.05.016","article-title":"Gene therapy for Leber hereditary optic neuropathy: low- and medium-dose visual results.","volume":"124","author":"Guy","year":"2017","journal-title":"Ophthalmology"},{"issue":"10089","key":"eoi180115r22","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/S0140-6736(17)30979-0","article-title":"Intravitreous injection of AAV2-sFLT01 in patients with advanced neovascular age-related macular degeneration: a phase 1, open-label trial.","volume":"390","author":"Heier","year":"2017","journal-title":"Lancet"},{"issue":"6","key":"eoi180115r23","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1089\/hum.2009.182","article-title":"Prevalence of serum IgG and neutralizing factors against adeno-associated virus (AAV) types 1, 2, 5, 6, 8, and 9 in the healthy population: implications for gene therapy using AAV vectors.","volume":"21","author":"Boutin","year":"2010","journal-title":"Hum Gene Ther"},{"issue":"4","key":"eoi180115r24","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1038\/nm1549","article-title":"CD8(+) T-cell responses to adeno-associated virus capsid in humans.","volume":"13","author":"Mingozzi","year":"2007","journal-title":"Nat Med"},{"issue":"1","key":"eoi180115r25","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1182\/blood-2013-01-306647","article-title":"Immune responses to AAV vectors: overcoming barriers to successful gene therapy.","volume":"122","author":"Mingozzi","year":"2013","journal-title":"Blood"},{"issue":"3","key":"eoi180115r26","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.crvi.2013.11.011","article-title":"Gene therapy for mitochondrial diseases: Leber hereditary optic neuropathy as the first candidate for a clinical trial.","volume":"337","author":"Cwerman-Thibault","year":"2014","journal-title":"C R Biol"},{"issue":"6","key":"eoi180115r27","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1016\/j.ophtha.2017.12.036","article-title":"Safety of rAAV2\/2-ND4 gene therapy for Leber hereditary optic neuropathy.","volume":"125","author":"Vignal","year":"2018","journal-title":"Ophthalmology"},{"issue":"20","key":"eoi180115r28","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1001\/jama.2013.281053","article-title":"World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects.","volume":"310","author":"World Medical Association","year":"2013","journal-title":"JAMA"},{"issue":"3","key":"eoi180115r29","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1016\/j.ajo.2005.03.057","article-title":"Standardization of uveitis nomenclature for reporting clinical data: results of the First International Workshop.","volume":"140","author":"Jabs","year":"2005","journal-title":"Am J Ophthalmol"},{"key":"eoi180115r31","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.trsl.2017.06.012","article-title":"Evaluation of tolerance to lentiviral LV-RPE65 gene therapy vector after subretinal delivery in non-human primates.","volume":"188","author":"Matet","year":"2017","journal-title":"Transl Res"},{"issue":"12","key":"eoi180115r32","doi-asserted-by":"publisher","first-page":"2648","DOI":"10.1016\/j.ymthe.2017.08.018","article-title":"AAV8 can induce innate and adaptive immune response in the primate eye.","volume":"25","author":"Reichel","year":"2017","journal-title":"Mol Ther"},{"issue":"20","key":"eoi180115r33","doi-asserted-by":"publisher","first-page":"1887","DOI":"10.1056\/NEJMoa1414221","article-title":"Long-term effect of gene therapy on Leber\u2019s congenital amaurosis.","volume":"372","author":"Bainbridge","year":"2015","journal-title":"N Engl J Med"},{"issue":"10097","key":"eoi180115r34","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1016\/S0140-6736(17)31868-8","article-title":"Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE65-mediated inherited retinal dystrophy: a randomised, controlled, open-label, phase 3 trial.","volume":"390","author":"Russell","year":"2017","journal-title":"Lancet"},{"issue":"3","key":"eoi180115r35","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1007\/s00439-016-1637-y","article-title":"Treatment of retinitis pigmentosa due to MERTK mutations by ocular subretinal injection of adeno-associated virus gene vector: results of a phase I trial.","volume":"135","author":"Ghazi","year":"2016","journal-title":"Hum Genet"},{"issue":"1","key":"eoi180115r36","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1001\/archophthalmol.2011.298","article-title":"Gene therapy for leber congenital amaurosis caused by RPE65 mutations: safety and efficacy in 15 children and adults followed up to 3 years.","volume":"130","author":"Jacobson","year":"2012","journal-title":"Arch Ophthalmol"},{"issue":"9923","key":"eoi180115r37","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1016\/S0140-6736(13)62117-0","article-title":"Retinal gene therapy in patients with choroideremia: initial findings from a phase 1\/2 clinical trial.","volume":"383","author":"MacLaren","year":"2014","journal-title":"Lancet"},{"issue":"88","key":"eoi180115r38","doi-asserted-by":"publisher","first-page":"88ra54","DOI":"10.1126\/scitranslmed.3002103","article-title":"Dosage thresholds for AAV2 and AAV8 photoreceptor gene therapy in monkey.","volume":"3","author":"Vandenberghe","year":"2011","journal-title":"Sci Transl Med"},{"issue":"11","key":"eoi180115r39","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1089\/hum.2017.150","article-title":"Unraveling the complex story of immune responses to AAV vectors trial after trial.","volume":"28","author":"Vandamme","year":"2017","journal-title":"Hum Gene Ther"},{"issue":"4","key":"eoi180115r40","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1089\/hum.2016.172","article-title":"Impact of AAV capsid-specific T-cell responses on design and outcome of clinical gene transfer trials with recombinant adeno-associated viral vectors: an evolving controversy.","volume":"28","author":"Ertl","year":"2017","journal-title":"Hum Gene Ther"},{"key":"eoi180115r30","author":"Thomasson","year":"2015"}],"container-title":["JAMA Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/\/jamaophthalmology\/article-pdf\/137\/4\/399\/17459388\/jamaophthalmology_bouquet_2019_oi_180115.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,4,12]],"date-time":"2019-04-12T02:29:13Z","timestamp":1555036153000},"score":1,"resource":{"primary":{"URL":"http:\/\/archopht.jamanetwork.com\/article.aspx?doi=10.1001\/jamaophthalmol.2018.6902"}},"subtitle":["A Secondary Analysis of a Phase 1\/2 Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2019,4,1]]},"references-count":40,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,4,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaophthalmol.2018.6902","relation":{},"ISSN":["2168-6165"],"issn-type":[{"value":"2168-6165","type":"print"}],"subject":[],"published":{"date-parts":[[2019,4,1]]}}}